{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:01:19Z","timestamp":1791421279570,"version":"4.3.3"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation Program of Jilin Province","award":["YDZJ202501ZYTS093"],"award-info":[{"award-number":["YDZJ202501ZYTS093"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06319-2","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T01:52:23Z","timestamp":1758505943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Advancements in the diagnosis and management of capecitabine-induced hand-foot syndrome"],"prefix":"10.1007","volume":"151","author":[{"given":"Baohua","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"6319_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.clcc.2011.05.004","volume":"11","author":"L Almeida da Cruz","year":"2012","unstructured":"Almeida da Cruz L, Hoff PM, Ferrari CL, Riechelmann RS (2012) Unilateral hand-foot syndrome: does it take sides? Case report and literature review. Clin Colorectal Cancer 11:82\u201384. https:\/\/doi.org\/10.1016\/j.clcc.2011.05.004","journal-title":"Clin Colorectal Cancer"},{"key":"6319_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/jco.1999.17.2.485","volume":"17","author":"JL Blum","year":"1999","unstructured":"Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485\u2013493. https:\/\/doi.org\/10.1200\/jco.1999.17.2.485","journal-title":"J Clin Oncol"},{"key":"6319_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","volume":"59","author":"JL Bolognia","year":"2008","unstructured":"Bolognia JL, Cooper DL, Glusac EJ (2008) Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 59:524\u2013529. https:\/\/doi.org\/10.1016\/j.jaad.2008.05.018","journal-title":"J Am Acad Dermatol"},{"key":"6319_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.12788\/jcso.0017","volume":"12","author":"T Braik","year":"2014","unstructured":"Braik T, Yim B, Evans AT, Kassem M, Mullane M, Lad T, Hussein L, Cleveland B, McDunn S (2014) Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy. J Community Support Oncol 12:65\u201370. https:\/\/doi.org\/10.12788\/jcso.0017","journal-title":"J Community Support Oncol"},{"key":"6319_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/014107680609900315","volume":"99","author":"B Caldwell","year":"2006","unstructured":"Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R (2006) Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 99:132\u2013140. https:\/\/doi.org\/10.1177\/014107680609900315","journal-title":"J R Soc Med"},{"key":"6319_CR6","doi-asserted-by":"publisher","first-page":"114232","DOI":"10.1016\/j.biopha.2023.114232","volume":"159","author":"M de With","year":"2023","unstructured":"de With M, van Doorn L, Maasland DC, Mulder TAM, Oomen-de Hoop E, Mostert B, Homs MYV, El Bouazzaoui S, Mathijssen RHJ, van Schaik RHN et al (2023a) Capecitabine-induced hand-foot syndrome: a pharmacogenetic study beyond DPYD. Biomed Pharmacother 159:114232. https:\/\/doi.org\/10.1016\/j.biopha.2023.114232","journal-title":"Biomed Pharmacother"},{"key":"6319_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101197","volume":"8","author":"M de With","year":"2023","unstructured":"de With M, Sadlon A, Cecchin E, Haufroid V, Thomas F, Joerger M, van Schaik RHN, Mathijssen RHJ, Largiad\u00e8r CR (2023b) Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. ESMO Open 8:101197. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101197","journal-title":"ESMO Open"},{"key":"6319_CR8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1610-0387.2010.07449.x","volume":"8","author":"A Degen","year":"2010","unstructured":"Degen A, Alter M, Schenck F, Satzger I, V\u00f6lker B, Kapp A, Gutzmer R (2010) The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges 8:652\u2013661. https:\/\/doi.org\/10.1111\/j.1610-0387.2010.07449.x","journal-title":"J Dtsch Dermatol Ges"},{"key":"6319_CR9","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/ptr.5857","volume":"31","author":"S Elyasi","year":"2017","unstructured":"Elyasi S, Shojaee FSR, Allahyari A, Karimi G (2017) Topical silymarin administration for prevention of capecitabine-induced hand-foot syndrome: a randomized, double-blinded, placebo-controlled clinical trial. Phytother Res 31:1323\u20131329. https:\/\/doi.org\/10.1002\/ptr.5857","journal-title":"Phytother Res"},{"key":"6319_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000327767","volume":"4","author":"KP Farr","year":"2011","unstructured":"Farr KP, Safwat A (2011) Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol 4:229\u2013235. https:\/\/doi.org\/10.1159\/000327767","journal-title":"Case Rep Oncol"},{"key":"6319_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1078155206069242","volume":"12","author":"SM Gressett","year":"2006","unstructured":"Gressett SM, Stanford BL, Hardwicke F (2006) Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 12:131\u2013141. https:\/\/doi.org\/10.1177\/1078155206069242","journal-title":"J Oncol Pharm Pract"},{"key":"6319_CR12","doi-asserted-by":"publisher","first-page":"11584","DOI":"10.1021\/acsnano.7b06524","volume":"11","author":"JI Griffin","year":"2017","unstructured":"Griffin JI, Wang G, Smith WJ, Vu VP, Scheinman R, Stitch D, Moldovan R, Moghimi SM, Simberg D (2017) Revealing dynamics of accumulation of systemically injected liposomes in the skin by intravital microscopy. ACS Nano 11:11584\u201311593. https:\/\/doi.org\/10.1021\/acsnano.7b06524","journal-title":"ACS Nano"},{"key":"6319_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1021\/acs.chemrestox.1c00317","volume":"35","author":"X He","year":"2022","unstructured":"He X, Wang J, Wang Q, Liu J, Yang X, He L, Hu H, Zeng S, Yu L, Qiu Y et al (2022) P38 MAPK, NF-\u03baB, and JAK-STAT3 signaling pathways involved in Capecitabine-induced hand-foot syndrome via interleukin 6 or interleukin 8 abnormal expression. Chem Res Toxicol 35:422\u2013430. https:\/\/doi.org\/10.1021\/acs.chemrestox.1c00317","journal-title":"Chem Res Toxicol"},{"key":"6319_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ijc.31065","volume":"142","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Siemerink EJM, Rosing H, Meijer J, Goorden SMI, Polstra AM, Zoetekouw L, Cats A, Schellens JHM, van Kuilenburg ABP (2018) Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency. Int J Cancer 142:424\u2013430. https:\/\/doi.org\/10.1002\/ijc.31065","journal-title":"Int J Cancer"},{"key":"6319_CR15","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1200\/jco.2014.60.4587","volume":"33","author":"RD Hofheinz","year":"2015","unstructured":"Hofheinz RD, Gencer D, Schulz H, Stahl M, Hegewisch-Becker S, Loeffler LM, Kronawitter U, Bolz G, Potenberg J, Tauchert F et al (2015) Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. J Clin Oncol 33:2444\u20132449. https:\/\/doi.org\/10.1200\/jco.2014.60.4587","journal-title":"J Clin Oncol"},{"key":"6319_CR16","doi-asserted-by":"publisher","DOI":"10.1117\/1.Jbo.21.4.047002","volume":"21","author":"MD Huang","year":"2016","unstructured":"Huang MD, Fuss H, Lademann J, Florek S, Patzelt A, Meinke MC, Jung S (2016) Detection of capecitabine (Xeloda\u00ae) on the skin surface after oral administration. J Biomed Opt 21:47002. https:\/\/doi.org\/10.1117\/1.Jbo.21.4.047002","journal-title":"J Biomed Opt"},{"key":"6319_CR17","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1002\/ijc.31269","volume":"142","author":"XZ Huang","year":"2018","unstructured":"Huang XZ, Chen Y, Chen WJ, Zhang X, Wu CC, Wang ZN, Wu J (2018) Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome. Int J Cancer 142:2567\u20132577. https:\/\/doi.org\/10.1002\/ijc.31269","journal-title":"Int J Cancer"},{"key":"6319_CR18","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s10147-025-02789-z","volume":"30","author":"Y Iimura","year":"2025","unstructured":"Iimura Y, Ishiguro H, Hashimoto H, Nojima M, Oyamada S, Mori K, Ariyoshi K, Kuroda S, Hirakawa S, Fujiwara N et al (2025) A randomized, double-blind, placebo-controlled phase III study evaluating the preventive effect of diclofenac cream on capecitabine-related hand-foot syndrome: study protocol of J-SUPPORT2401\/JORTC-SUP06 (J-DIRECT). Int J Clin Oncol 30:1553\u20131561. https:\/\/doi.org\/10.1007\/s10147-025-02789-z","journal-title":"Int J Clin Oncol"},{"key":"6319_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1177\/1078155215587345","volume":"22","author":"AI Ilich","year":"2016","unstructured":"Ilich AI, Danilak M, Kim CA, Mulder KE, Spratlin JL, Ghosh S, Chambers CR, Sawyer MB (2016) Effects of gender on capecitabine toxicity in colorectal cancer. J Oncol Pharm Pract 22:454\u2013460. https:\/\/doi.org\/10.1177\/1078155215587345","journal-title":"J Oncol Pharm Pract"},{"key":"6319_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000529851","volume":"101","author":"Y Kanbayashi","year":"2023","unstructured":"Kanbayashi Y, Taguchi T, Ishikawa T, Otsuji E, Takayama K (2023) Risk factors of capecitabine-induced hand-foot syndrome: a single-institution, retrospective study. Oncology 101:407\u2013414. https:\/\/doi.org\/10.1159\/000529851","journal-title":"Oncology"},{"key":"6319_CR21","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1200\/jco.2010.29.1807","volume":"28","author":"YK Kang","year":"2010","unstructured":"Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, Ryu MH, Chang HM, Lee JL, Kim TW (2010) Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 28:3824\u20133829. https:\/\/doi.org\/10.1200\/jco.2010.29.1807","journal-title":"J Clin Oncol"},{"key":"6319_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15774","volume":"35","author":"YS Kao","year":"2022","unstructured":"Kao YS, Lo CH, Tu YK, Hung CH (2022) Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: a network meta-analysis of randomized control trials. Dermatol Ther 35:e15774. https:\/\/doi.org\/10.1111\/dth.15774","journal-title":"Dermatol Ther"},{"key":"6319_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00280-025-04794-5","volume":"95","author":"AM Kettana","year":"2025","unstructured":"Kettana AM, Mostafa TM, Ghannam AA, El-Afify DR (2025) Protective effect of celecoxib against capecitabine induced hand and foot syndrome in patients with colorectal cancer. Cancer Chemother Pharmacol 95:72. https:\/\/doi.org\/10.1007\/s00280-025-04794-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"6319_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1177\/10781552231192107","volume":"30","author":"R Kieran","year":"2024","unstructured":"Kieran R, Mitchell T, Fazari AA, Chinoy A, Moloney C, McCaffrey J (2024) DPD deficiency in an Irish oncology centre: prevalence and clinical implications. J Oncol Pharm Pract 30:977\u2013982. https:\/\/doi.org\/10.1177\/10781552231192107","journal-title":"J Oncol Pharm Pract"},{"key":"6319_CR25","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2020.442","volume":"14","author":"JJM Kwakman","year":"2020","unstructured":"Kwakman JJM, Elshot YS, Punt CJA, Koopman M (2020) Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev 14:442. https:\/\/doi.org\/10.4081\/oncol.2020.442","journal-title":"Oncol Rev"},{"key":"6319_CR26","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/ncc.0000000000001008","volume":"45","author":"TC Lan","year":"2022","unstructured":"Lan TC, Tsou PH, Tam KW, Huang TW (2022) Effect of urea cream on hand-foot syndrome in patients receiving chemotherapy: a meta-analysis. Cancer Nurs 45:378\u2013386. https:\/\/doi.org\/10.1097\/ncc.0000000000001008","journal-title":"Cancer Nurs"},{"issue":"Suppl 1","key":"6319_CR27","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.ejon.2004.06.007","volume":"8","author":"Y Lassere","year":"2004","unstructured":"Lassere Y, Hoff P (2004) Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 8(Suppl 1):S31-40. https:\/\/doi.org\/10.1016\/j.ejon.2004.06.007","journal-title":"Eur J Oncol Nurs"},{"key":"6319_CR28","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/jan.12639","volume":"71","author":"A Law","year":"2015","unstructured":"Law A, Dyson S, Anthony D (2015) An exploratory study to identify risk factors for the development of capecitabine-induced palmar plantar erythrodysesthesia (PPE). J Adv Nurs 71:1825\u20131832. https:\/\/doi.org\/10.1111\/jan.12639","journal-title":"J Adv Nurs"},{"key":"6319_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.746910","volume":"12","author":"M Li","year":"2021","unstructured":"Li M, Chen J, Liu S, Sun X, Xu H, Gao Q, Chen X, Xi C, Huang D, Deng Y et al (2021) Spermine-related DNA hypermethylation and elevated expression of genes for collagen formation are susceptible factors for chemotherapy-induced hand-foot syndrome in Chinese colorectal cancer patients. Front Pharmacol 12:746910. https:\/\/doi.org\/10.3389\/fphar.2021.746910","journal-title":"Front Pharmacol"},{"key":"6319_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/ced.14486","volume":"46","author":"S Lian","year":"2021","unstructured":"Lian S, Zhang X, Zhang Y, Zhao Q (2021) Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis. Clin Exp Dermatol 46:629\u2013635. https:\/\/doi.org\/10.1111\/ced.14486","journal-title":"Clin Exp Dermatol"},{"key":"6319_CR31","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1021\/acs.chemrestox.6b00215","volume":"29","author":"Y Lou","year":"2016","unstructured":"Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, Zeng S (2016) Possible pathways of capecitabine-induced hand-foot syndrome. Chem Res Toxicol 29:1591\u20131601. https:\/\/doi.org\/10.1021\/acs.chemrestox.6b00215","journal-title":"Chem Res Toxicol"},{"key":"6319_CR32","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00280-021-04233-1","volume":"87","author":"M Maillard","year":"2021","unstructured":"Maillard M, Eche-Gass A, Ung M, Brice A, Marsili S, Montastruc M, Puisset F, Thomas F (2021) Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines. Cancer Chemother Pharmacol 87:579\u2013583. https:\/\/doi.org\/10.1007\/s00280-021-04233-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"6319_CR61","doi-asserted-by":"crossref","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH,Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H,Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M (2017) Adjuvant Capecitabine for Breast Cancer afterPreoperative Chemotherapy. N Engl J Med 376(22):2147-2159. doi:10.1056\/NEJMoa1612645","DOI":"10.1056\/NEJMoa1612645"},{"key":"6319_CR33","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1158\/1078-0432.Ccr-06-0747","volume":"12","author":"LK Mattison","year":"2006","unstructured":"Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB (2006) Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 12:5491\u20135495. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-0747","journal-title":"Clin Cancer Res"},{"key":"6319_CR34","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.pain.2011.02.019","volume":"152","author":"T Miki","year":"2011","unstructured":"Miki T, Matsunami M, Nakamura S, Okada H, Matsuya H, Kawabata A (2011) ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. Pain 152:1373\u20131381. https:\/\/doi.org\/10.1016\/j.pain.2011.02.019","journal-title":"Pain"},{"key":"6319_CR35","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","volume":"71","author":"KK Miller","year":"2014","unstructured":"Miller KK, Gorcey L, McLellan BN (2014) Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 71:787\u2013794. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.019","journal-title":"J Am Acad Dermatol"},{"key":"6319_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","volume":"1","author":"E Nagore","year":"2000","unstructured":"Nagore E, Insa A, Sanmart\u00edn O (2000) Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot\u2019) syndrome. Incidence, recognition and management. Am J Clin Dermatol 1:225\u2013234. https:\/\/doi.org\/10.2165\/00128071-200001040-00004","journal-title":"Am J Clin Dermatol"},{"key":"6319_CR37","first-page":"101","volume":"73","author":"P Narasimhan","year":"2004","unstructured":"Narasimhan P, Narasimhan S, Hitti IF, Rachita M (2004) Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Cutis 73:101\u2013106","journal-title":"Cutis"},{"key":"6319_CR38","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1080\/14740338.2016.1238067","volume":"15","author":"V Nikolaou","year":"2016","unstructured":"Nikolaou V, Syrigos K, Saif MW (2016) Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf 15:1625\u20131633. https:\/\/doi.org\/10.1080\/14740338.2016.1238067","journal-title":"Expert Opin Drug Saf"},{"key":"6319_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10549-016-3756-5","volume":"156","author":"TF Nishijima","year":"2016","unstructured":"Nishijima TF, Suzuki M, Muss HB (2016) A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 156:227\u2013236. https:\/\/doi.org\/10.1007\/s10549-016-3756-5","journal-title":"Breast Cancer Res Treat"},{"key":"6319_CR40","doi-asserted-by":"publisher","first-page":"8655","DOI":"10.1007\/s00520-022-07175-3","volume":"30","author":"JGP Pandy","year":"2022","unstructured":"Pandy JGP, Franco PIG, Li RK (2022) Prophylactic strategies for hand-foot syndrome\/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. Support Care Cancer 30:8655\u20138666. https:\/\/doi.org\/10.1007\/s00520-022-07175-3","journal-title":"Support Care Cancer"},{"key":"6319_CR41","doi-asserted-by":"publisher","first-page":"175883592210869","DOI":"10.1177\/17588359221086911","volume":"14","author":"A Rodr\u00edguez-Garzotto","year":"2022","unstructured":"Rodr\u00edguez-Garzotto A, Iglesias-Docampo L, D\u00edaz-Garc\u00eda CV, Ruppen I, Xim\u00e9nez-Emb\u00fan P, G\u00f3mez C, Rodr\u00edguez-Peralto JL, de Frutos JO, Lopez-Martin JA, Gr\u00e1valos C et al (2022) Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies. Ther Adv Med Oncol 14:17588359221086912. https:\/\/doi.org\/10.1177\/17588359221086911","journal-title":"Ther Adv Med Oncol"},{"key":"6319_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1517\/14740338.2011.546342","volume":"10","author":"MW Saif","year":"2011","unstructured":"Saif MW (2011) Capecitabine and hand-foot syndrome. Expert Opin Drug Saf 10:159\u2013169. https:\/\/doi.org\/10.1517\/14740338.2011.546342","journal-title":"Expert Opin Drug Saf"},{"key":"6319_CR43","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1200\/jco.23.01730","volume":"42","author":"A Santhosh","year":"2024","unstructured":"Santhosh A, Sharma A, Bakhshi S, Kumar A, Sharma V, Malik PS, Pramanik R, Gogia A, Prasad CP, Sehgal T et al (2024) Topical diclofenac for prevention of capecitabine-associated hand-foot syndrome: a double-blind randomized controlled trial. J Clin Oncol 42:1821\u20131829. https:\/\/doi.org\/10.1200\/jco.23.01730","journal-title":"J Clin Oncol"},{"key":"6319_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00280-023-04552-5","volume":"92","author":"M Shafiei","year":"2023","unstructured":"Shafiei M, Galettis P, Beale P, Reuter SE, Martin JH, McLachlan AJ, Blinman P (2023) Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer: a pilot study. Cancer Chemother Pharmacol 92:135\u2013139. https:\/\/doi.org\/10.1007\/s00280-023-04552-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"6319_CR45","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071\u20131080. https:\/\/doi.org\/10.1056\/NEJMoa050405","journal-title":"N Engl J Med"},{"key":"6319_CR46","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3892\/mco.2018.1689","volume":"9","author":"S Suzuki","year":"2018","unstructured":"Suzuki S, Nawata S, Inada Y, Sato D, Kusano J, Ichikura D, Torigoe K, Ishitsuka K, Sato F, Sakai H et al (2018) A cross-sectional survey of methods for controling hand-foot syndrome in patients receiving capecitabine treatment. Mol Clin Oncol 9:443\u2013448. https:\/\/doi.org\/10.3892\/mco.2018.1689","journal-title":"Mol Clin Oncol"},{"key":"6319_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aar5514","author":"M Takahashi","year":"2019","unstructured":"Takahashi M, Izawa K, Urai M, Yamanishi Y, Maehara A, Isobe M, Matsukawa T, Kaitani A, Takamori A, Uchida S et al (2019) The phytosphingosine-CD300b interaction promotes zymosan-induced, nitric oxide-dependent neutrophil recruitment. Sci Signal. https:\/\/doi.org\/10.1126\/scisignal.aar5514","journal-title":"Sci Signal"},{"key":"6319_CR48","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3389\/fphar.2016.00310","volume":"7","author":"L Timmers","year":"2016","unstructured":"Timmers L, Boons CC, Mangnus D, Van de Ven PM, Van den Berg PH, Beeker A, Swart EL, Honeywell RJ, Peters GJ, Boven E et al (2016) Adherence and patients\u2019 experiences with the use of capecitabine in daily practice. Front Pharmacol 7:310. https:\/\/doi.org\/10.3389\/fphar.2016.00310","journal-title":"Front Pharmacol"},{"key":"6319_CR49","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s12282-018-0879-z","volume":"25","author":"T Toyama","year":"2018","unstructured":"Toyama T, Yoshimura A, Hayashi T, Kobayashi N, Saito K, Tsuneizumi M, Sawaki M, Hattori M, Nakada T, Yokota I et al (2018) A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. Breast Cancer 25:729\u2013735. https:\/\/doi.org\/10.1007\/s12282-018-0879-z","journal-title":"Breast Cancer"},{"key":"6319_CR50","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/jnci\/djaa124","volume":"113","author":"AD Wagner","year":"2021","unstructured":"Wagner AD, Grothey A, Andre T, Dixon JG, Wolmark N, Haller DG, Allegra CJ, de Gramont A, VanCutsem E, Alberts SR et al (2021) Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34 640 patients in the ACCENT database. J Natl Cancer Inst 113:400\u2013407. https:\/\/doi.org\/10.1093\/jnci\/djaa124","journal-title":"J Natl Cancer Inst"},{"key":"6319_CR51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"X Wang","year":"2021","unstructured":"Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH et al (2021) Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA 325:50\u201358. https:\/\/doi.org\/10.1001\/jama.2020.23370","journal-title":"JAMA"},{"key":"6319_CR52","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.31557\/apjcp.2024.25.6.2203","volume":"25","author":"L Wanichtanom","year":"2024","unstructured":"Wanichtanom L, Vrakornvoravuti G, Boonsiri M, Suthepwanon A (2024) A randomized single-blinded phase II trial comparing efficacy and quality of life of topical Aloe vera gel plus urea cream versus urea cream alone for prevention of hand foot syndrome in cancer patients receiving capecitabine. Asian Pac J Cancer Prev 25:2203\u20132210. https:\/\/doi.org\/10.31557\/apjcp.2024.25.6.2203","journal-title":"Asian Pac J Cancer Prev"},{"key":"6319_CR53","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/ijc.34046","volume":"151","author":"K Watts","year":"2022","unstructured":"Watts K, Wills C, Madi A, Palles C, Maughan TS, Kaplan R, Al-Tassan NA, Kerr R, Kerr DJ, Houlston RS et al (2022) Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. Int J Cancer 151:957\u2013966. https:\/\/doi.org\/10.1002\/ijc.34046","journal-title":"Int J Cancer"},{"key":"6319_CR54","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41416-022-02039-3","volume":"128","author":"B Yang","year":"2023","unstructured":"Yang B, Xie X, Lv D, Hu J, Chen Y, Wu Z, Luo S, Zhang S (2023) Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil. Br J Cancer 128:219\u2013231. https:\/\/doi.org\/10.1038\/s41416-022-02039-3","journal-title":"Br J Cancer"},{"key":"6319_CR55","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1001\/jamaoncol.2017.1269","volume":"3","author":"YS Yap","year":"2017","unstructured":"Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, Tham CK, Wong NS, Lo SK, Dent RA, Tan S et al (2017) Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial. JAMA Oncol 3:1538\u20131545. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1269","journal-title":"JAMA Oncol"},{"key":"6319_CR56","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1124\/jpet.104.071548","volume":"311","author":"K Yuhki","year":"2004","unstructured":"Yuhki K, Ueno A, Naraba H, Kojima F, Ushikubi F, Narumiya S, Oh-ishi S (2004) Prostaglandin receptors EP2, EP3, and IP mediate exudate formation in carrageenin-induced mouse pleurisy. J Pharmacol Exp Ther 311:1218\u20131224. https:\/\/doi.org\/10.1124\/jpet.104.071548","journal-title":"J Pharmacol Exp Ther"},{"key":"6319_CR57","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00432-010-0958-9","volume":"137","author":"RX Zhang","year":"2011","unstructured":"Zhang RX, Wu XJ, Lu SX, Pan ZZ, Wan DS, Chen G (2011) The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II\/III colorectal cancer: a phase II randomized prospective study. J Cancer Res Clin Oncol 137:953\u2013957. https:\/\/doi.org\/10.1007\/s00432-010-0958-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"6319_CR58","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/annonc\/mdr400","volume":"23","author":"RX Zhang","year":"2012","unstructured":"Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ, Chen G (2012) Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 23:1348\u20131353. https:\/\/doi.org\/10.1093\/annonc\/mdr400","journal-title":"Ann Oncol"},{"key":"6319_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/s0254-6272(14)60047-9","volume":"34","author":"C Zhao","year":"2014","unstructured":"Zhao C, Chen J, Yu B, Wu X, Dai C, Zhou C, Chen X (2014) Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome. J Tradit Chin Med 34:10\u201314. https:\/\/doi.org\/10.1016\/s0254-6272(14)60047-9","journal-title":"J Tradit Chin Med"},{"key":"6319_CR60","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3727\/096504019x15605078731913","volume":"28","author":"J Zhao","year":"2020","unstructured":"Zhao J, Zhang X, Cui X, Wang D, Zhang B, Ban L (2020) Loss of fingerprints as a side effect of capecitabine therapy: case report and literature review. Oncol Res 28:103\u2013106. https:\/\/doi.org\/10.3727\/096504019x15605078731913","journal-title":"Oncol Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06319-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06319-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06319-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T20:46:53Z","timestamp":1761338813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06319-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6319"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06319-2","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"265"}}